This study evaluates the safety and tolerability of TN-201, a gene therapy, in adults with hypertrophic cardiomyopathy caused by a mutation in the MYBPC3 gene. Adults with a MYBPC3 mutation, symptoms (NYHA Class II or III), and a certain level of preserved heart function may take part. The study is in Phase 1/Phase 2 and is currently enrolling participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * MYBPC3 mutation * Hypertrophic Cardiomyopathy (obstructive and nonobstructive) * Left Ventricular Ejection Fraction ≥45% * NYHA Functional Class II or III symptoms * NT-proBNP ≥160pg/ml Exclusion Criteria: * High AAV9 neutralizing antibody titer